Canaccord raised the firm’s price target on Atara Biotherapeutics (ATRA) to $25 from $17 and keeps a Buy rating on the shares. The firm said they see a reasonable chance for FDA approval of tab-cel in EBV+ post-transplant lymphoproliferative disease (EBV+ PTLD) by the upcoming action date of January 11, 2026. The $40M milestone upon approval will help to reinvigorate its pipeline.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATRA:
- ATRA Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Atara Biotherapeutics price target raised to $18 from $16 at Mizuho
- Atara Biotherapeutics price target raised to $140 from $131 at Mizuho
- Potential FDA Approval of Atara’s Tab-cel Therapy: A Game-Changer for Future Growth and CAR T Program Revitalization
- Atara Biotherapeutics reports Q3 EPS (32c), consensus (67c)